Although the exact cut-off value is yet to be validated, similar results were obtained using the above cut-off values, suggesting these values can be used to identify DLBCL patients treated with R-CHOP and who achieved CMR, that are at higher risk of relapse. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.